Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022
|
By LabMedica International staff writers Posted on 16 Nov 2022 |

Eurotrol, Inc. (Elizabethtown, KY, USA) is demonstrating its innovative, patented packaging concept that will modernize the in vitro diagnostic market at MEDICA 2022 Trade Fair being held in Düsseldorf, Germany from 14-17th November.
Eurotrol’s CueSee Ringe is being touted as the future of blood gas controls. A special glass ampoule is sealed inside the CueSee Ringe device. This ampoule breaks with a simple turning motion without the risk of cutting fingers on glass particles or coming into contact with the liquid. After this activation step, the CueSee Ringe functions identically to a standard syringe. The liquid inside the ampoule is not deteriorated by environmental contamination, which reduces pre-analytical errors. This concept is ideal for solutions typically stored in ampoules for quality control, calibration verification, proficiency testing, competency assessment, method validations, and lot comparisons.
At MEDICA 2022, Eurotrol is also demonstrating a breakthrough product, the CueSee CO-OX. Co-oximetry determines the levels of the various derivatives of hemoglobin (Hb) in a patient’s blood. Being able to accurately detect and measure the amount of oxyhemoglobin available to carry O2 to the cells of the body is essential, as well as measurements of the abnormal Hb derivatives: carboxyhemoglobin and methemoglobin. It is crucial that co-oximetry testing for these fractions are validated and proven to measure all, at normal and abnormal levels. CueSee CO-OX has proven performance to help meet everyone’s needs. Eurotrol has revolutionized quality control for CO-oximeters by developing CueSee CO-OX with real hemoglobin derivatives performing like patient samples. Packaged in the ACU-Drop II, this dual-chambered device keeps the oxyhemoglobin separated from the methemoglobin to provide a long shelf-life.
Related Links:
Eurotrol, Inc.
Latest MEDICA 2022 News
- Bosch Demonstrates Vivalytic All-In-One PCR Analyzer at MEDICA 2022
- Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
- Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022
- Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022
- Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases

- Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes
- Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022
- EDAN Takes its Solutions up a Notch at MEDICA 2022
- Bioneer Presents Near-Patient POC Molecular Diagnostic System at MEDICA 2022
- Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022
- MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
- Oxford Immunotec Showcases Automated T-SPOT.TB Test at MEDICA 2022
- Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022
- Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022
- Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections
- Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022
Channels
Clinical Chemistry
view channel
Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
Iron deficiency is one of the world’s most common nutritional disorders and can be difficult to diagnose where access to laboratories and trained personnel is limited. Women and children in low-resource... Read more
Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read moreMolecular Diagnostics
view channel
Genetic Risk Score Identifies Type 1 Diabetes in MODY Testing
Accurately distinguishing maturity-onset diabetes of the young from type 1 diabetes is difficult in routine care, especially when onset occurs in adolescence or early adulthood. Although maturity-onset... Read more
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
Glioma surgery depends on distinguishing infiltrative tumor from functional brain tissue, but microscopic spread beyond visible margins makes this difficult. Conventional frozen sections provide rapid... Read moreTechnology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read moreIndustry
view channel
AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
Imagene AI has joined the Proscia Ready partner alliance to integrate its hematoxylin and eosin (H&E) screening tools and immunohistochemistry (IHC) image-analysis capabilities with Proscia’s Concentriq... Read more








